Translating Next-Generation Science Into Transformative Gene Therapies Learn About Our Programs

News & Events Press Releases March 25, 2026 Encoded Therapeutics Announces FDA Alignment, Initiation of Pivotal Study, and ASGCT Presidential Symposium Presentation of ETX101 in Dravet …

Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. Our diversity – whether gender, ethnicity, sexual …

Jan 8, 2026 · Encoded Therapeutics Highlights Progress in Dravet Syndrome Program and Pipeline Ahead of Company Presentation at 44th Annual J.P. Morgan Healthcare Conference – Positive …

Dec 16, 2025 · Encoded Therapeutics Strengthens Clinical Leadership Team with Appointment of Professor Joseph Sullivan, M.D., as Vice President of Clinical Development – Globally recognized …

Encoded is developing ETX101, a potential one-time, disease-modifying gene regulation therapy for SCN1A+ Dravet syndrome. ETX101, Encoded’s lead program, is specifically designed to address the …

Data from observational studies and clinical trials, which depend on volunteer participants, form the foundation of regulatory authorities’ decisions to approve new therapies for broader use.

Encoded is building an internally developed pipeline of best- and potentially first-in-class therapies focused on pediatric central nervous system (CNS) disorders.

Encoded team members are creative, passionate and collaborative. We invite you to join us in our mission to develop transformative therapies by fostering a culture of relentless patient focus, …

Encoded Therapeutics Reports Clinical Progress of ETX101 Gene Therapy for Dravet Syndrome, Recaps 2024 Corporate Achievements and Provides 2025 Outlook POLARIS program, launched in …